Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Partner and localizer of BRCA2 (PALB2) is a tumor suppressor protein essential for homologous recombination-mediated repair of DNA double-strand breaks. It acts as a scaffold, recruiting and stabilizing BRCA2 and RAD51 at sites of DNA damage, and directly interacts with BRCA1 to promote the assembly of DNA repair complexes. PALB2 helps to maintain genomic integrity, prevent accumulation of DNA damage, and suppress tumorigenesis. Inherited monoallelic mutations confer a significantly increased risk of breast, pancreatic, and ovarian cancers, whereas biallelic mutations cause Fanconi anemia subtype N, characterized by early-onset cancer predisposition and hematologic disorders. PALB2-deficient cancers may be sensitive to synthetic lethal approaches such as PARP inhibition[1][3][4][5][6][7].
Synthetic lethality in homologous recombination-deficient cancers by PARP inhibition
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Partner and localizer of BRCA2 (PALB2).